Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/29/2005WO2005123659A1 Method of synthesising (1s)-4,5-dimethoxy-1- (methylaminomethyl)-benzocyclobutane and the addition salts thereof, and use of same for the synthesis of ivabradine and the pharmaceutically-acceptable addition salts thereof
12/29/2005WO2005123651A1 L-2-(α-HYDROXYPENTYL)BENZOATES, THE PREPARATION AND THE USE THEREOF
12/29/2005WO2005123645A1 Regulators of bacterial signalling pathways
12/29/2005WO2005123642A1 Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
12/29/2005WO2005123193A2 Treatments comprising strontium for rheumatic and arthritic diseases and pain
12/29/2005WO2005123192A2 Improving pain treatment with strontium combinations
12/29/2005WO2005123191A1 Pyk2 inhibitors for stimulation of osteoblast function
12/29/2005WO2005123149A1 A lock solution for medical devices
12/29/2005WO2005123140A2 Preparation of macromolecular conjugates by four-component condensation reaction
12/29/2005WO2005123137A2 Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride
12/29/2005WO2005123136A1 Antiinflammatory and analgesic preparation for external use
12/29/2005WO2005123135A1 Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide
12/29/2005WO2005123134A2 A controlled release delivery system for metformin
12/29/2005WO2005123133A1 A process for preparing ibuprofen soft gelatin capsules
12/29/2005WO2005123132A2 Use of liver-selective glucokinase activators
12/29/2005WO2005123130A2 Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
12/29/2005WO2005123128A2 Methods for treating conditions associated with masp-2 dependent complement activation
12/29/2005WO2005123103A1 Topical compositions and methods for epithelial-related conditions
12/29/2005WO2005123097A1 Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
12/29/2005WO2005123096A2 Compositions and methods of use of dimer digallates
12/29/2005WO2005123095A1 Anti-parasitic uses of borinic acid complexes
12/29/2005WO2005123094A2 Treatment or prevention of skin conditions or tissue conditions in animals using boryloxypyridylmethanones
12/29/2005WO2005123093A2 Ophthalmic formulations including selective alpha 1 antagonists
12/29/2005WO2005123092A1 Composition for the treatment of psoriasis comprising a silicone agent, a corticosteroid and vitamin d or a derivative thereof
12/29/2005WO2005123091A1 Composition in the form of a spray comprising a combination of clobetasol propionate and calcitriol, an alcohol phase and an oily phase
12/29/2005WO2005123090A1 Composition in spray form comprising a combination of a corticoid and a vitamin d derivative in an oily phase
12/29/2005WO2005123089A2 Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
12/29/2005WO2005123088A1 Solid orally ingestible formulations of tetrodotoxin
12/29/2005WO2005123087A2 C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
12/29/2005WO2005123086A2 Ziprasidone dosage form
12/29/2005WO2005123085A1 Orally-administered aqueous risperidone solution
12/29/2005WO2005123084A1 Orally disintegrating pharmaceutical composition comprising risperidone
12/29/2005WO2005123083A1 Compositions, devices and methods for treating cardiovascular disease
12/29/2005WO2005123082A1 An anti-hyperlipemia composition
12/29/2005WO2005123081A2 (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia
12/29/2005WO2005123080A2 Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
12/29/2005WO2005123079A2 Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
12/29/2005WO2005123078A1 Liposome preparation containing slightly water-soluble camptothecin
12/29/2005WO2005123077A2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof
12/29/2005WO2005123076A2 Pharmaceutical compositions
12/29/2005WO2005123075A2 Controlling angiogenesis with anabaseine analogs
12/29/2005WO2005123073A1 Marine compounds with calcium channel blocking properties for the treatment of cognitive or neurodegenerative diseases
12/29/2005WO2005123072A1 Methods and compositions for the treatment of pulmonary diseases
12/29/2005WO2005123071A1 Methods of using albuterol and calcium activated potassium channel openers
12/29/2005WO2005123070A1 Dual blockade of renin-angiotensin system reduces connective tissue growth factor levels in diabetic nephropathy
12/29/2005WO2005123069A2 Gram-positive carbapenem antibacterials and processes for their preparation
12/29/2005WO2005123068A2 Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
12/29/2005WO2005123067A1 Peptidomimetic inhibitors of retroviral proteases and their use as antivirals
12/29/2005WO2005123066A1 Carbapenem antibacterials with gram-negative activity and processes for their preparation
12/29/2005WO2005123065A1 Chemokine receptor antagonistic medicinal composition
12/29/2005WO2005123064A1 Adrenergic complement inhaler comprising compounds such as ascorbates tocopherols or polycaboxylic acid chelators
12/29/2005WO2005123063A1 Compositions for urinary dysfunction and edema containing decursin and/or decursinol angelate, or angelica extract containing decursin and /or decursinol angelate
12/29/2005WO2005123062A1 Inflammation inhibitor comprising zinc salt of acylamino acid
12/29/2005WO2005123061A1 Pharmaceutical compositions containing polyunsaturated fatty acid and at least one of an immunosuppressive agent or an antineoplastic agent
12/29/2005WO2005123060A1 A pharmaceutical composition and its use
12/29/2005WO2005123059A1 Alpha-ketoglutatic acid or derivatives thereof for the treatment of osteoporosis and related diseases
12/29/2005WO2005123058A1 Antiaging agent
12/29/2005WO2005123057A1 Antimicrobial compositions and methods of use thereof
12/29/2005WO2005123056A1 Use of alpha-ketoglutarate and related compounds for lowering plasma lipids
12/29/2005WO2005123055A2 Methods for treating inflammatory disorders
12/29/2005WO2005123054A1 Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives
12/29/2005WO2005123053A2 Use of cb2 receptors agonists for the treatment of huntington’s disease
12/29/2005WO2005123052A1 Drug composition containing ambroxol and erdosteine or acetylcysteine
12/29/2005WO2005123051A2 Resorcinol derivatives for lowering blood pressure
12/29/2005WO2005123050A2 Five-membered heterocycles useful as serine protease inhibitors
12/29/2005WO2005123049A2 A pharmaceutical composition for increasing the mitochondrial genesis
12/29/2005WO2005123048A2 Screening methods using c-abl, fyn and syk in combination with tau protein
12/29/2005WO2005123040A1 Tablet rapidly disintegrating in mouth
12/29/2005WO2005123030A1 Topical compositions containing 5'-adenosine-diphosphate ribose
12/29/2005WO2005123010A1 Preventing shin damage
12/29/2005WO2005122795A1 Topical application of marine oils to foods
12/29/2005WO2005122794A1 Composition containing plant extract and material derived from milk
12/29/2005WO2005122793A1 Food composition with wine extract and grape juice extract
12/29/2005WO2005122791A2 Improvement of barrier integrity in hiv patients with fatty acids
12/29/2005WO2005122767A1 Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
12/29/2005WO2005122739A2 Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
12/29/2005WO2005122678A2 A pharmaceutical composition having prokinetic effect and comprising o-(3-piperidino-2-hydroxypropyl) nicotinic amidoxime
12/29/2005WO2005122671A2 An improved process for the preparation of oxcarbazepine and related intermediates
12/29/2005WO2005115384A3 Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
12/29/2005WO2005108403A3 Dealkylated derivatives of pyrrolo[2,1-b]benzothiazepines with atypical antipsychotic activity
12/29/2005WO2005107765A3 Heart treatment method
12/29/2005WO2005107754A3 Transdermal iontophoretic delivery of piperazinyl-2(3h)-benzoxazolone compounds
12/29/2005WO2005107753A3 Naltrexone long acting formulations and methods of use
12/29/2005WO2005105995A3 RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/29/2005WO2005105780A3 Compositions useful as inhibitors of rock and other protein kinases
12/29/2005WO2005102380A3 Methods of inhibiting inflammation
12/29/2005WO2005102337A3 Use of a sphingoid base associated with nicotinic acid or a nicotinic acid amide in the form of a depigmentation agent
12/29/2005WO2005099687A3 Analogs of salinosporamide a
12/29/2005WO2005097089A9 Derivatives of leinamycin for use as anticancer agents
12/29/2005WO2005096717A3 Agent exhibiting hepatoprotective properties
12/29/2005WO2005094322A3 Effective treatment of tumors and cancer with triciribine and related compounds
12/29/2005WO2005091872A3 Pharmaceutical composition and method for the transdermal delivery of magnesium
12/29/2005WO2005086656A3 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
12/29/2005WO2005082348A3 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
12/29/2005WO2005081753A3 Nitric oxide-releasing molecules
12/29/2005WO2005079398A3 Drug conjugates
12/29/2005WO2005077122A3 Compounds and compositions as lxr modulators
12/29/2005WO2005076011A3 Use of glut1 transporter expressed in blood brain barrier cells for screening for pharmacologically active substances
12/29/2005WO2005074536A3 Compositions and methods using proton pump inhibitors
12/29/2005WO2005072343A3 Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use
1 ... 4415 4416 4417 4418 4419 4420 4421 4422 4423 4424 4425 4426 4427 4428 4429 4430 4431 4432 4433 4434 4435 ... 7860